ruplizumab
mAbexperimental
Ruplizumab is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms, while another study only found thrombocytopenia. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 1999 (NCT00001857)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- CD40 ligandINHIBITOR
CD40LG inhibitor
Discontinued early due to thromboses in some recipients.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRuplizumab ↗
- ChEMBLCHEMBL2108767 ↗
Also known as
- antova
- bg9588
- bg-9588
- hu5c8
- ruplizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00001789 | Phase 2 | Jun 1, 1999 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
| NCT00001857 | Phase 2 | May 1, 1999 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Government | 1 | 1 | 1 | 1999 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 1 | 1 | 1999 |
2 organizations
Page 1 / 1